BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
TIACCI, Enrico;DE CAROLIS, LUCA;FALZETTI, Franca;ASCANI, Stefano;CAPPONI, Monia;MARTELLI, Maria Paola;FALINI, Brunangelo;
2015
Abstract
BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.